AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease

Atherosclerosis

Volumn 194, Issue 2, 2007, Pages 439-445

  Warnholtz, Ascan ^a   Ostad, Mir Abolfazl ^a   Heitzer, Thomas ^b   Thuneke, Felix ^b   Fröhlich, Meike ^b   Tschentscher, Peter ^c   Schwedhelm, Edzard ^c   Böger, Rainer ^c   Meinertz, Thomas ^b   Munzel, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HEART CENTER HAMBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acetylcholine; Endothelial dysfunction; Flow mediated dilation; Irbesartan

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IRBESARTAN; ISOPROSTANE; N(G),N(G) DIMETHYLARGININE; PLACEBO;

ADULT; AMINO ACID BLOOD LEVEL; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; EXCRETION; FEMALE; HUMAN; INFUSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VASOMOTOR REFLEX;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; TETRAZOLES; VASODILATION;

EID: 34848814719     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.08.034     Document Type: Article

References (23)

1. Mollnau H., Wendt M., Szocs K., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90 (2002) E58-E65
2. Higashi Y., Chayama K., and Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 133-148
3. Mancini G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94 (1996) 258-265
4. Oelze M., Mollnau H., Hoffmann N., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 87 (2000) 999-1005
5. Warnholtz A., Nickenig G., Schulz E., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
6. Hornig B., Landmesser U., Kohler C., et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103 (2001) 799-805
7. Prasad A., Tupas-Habib T., Schenke W.H., et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 101 (2000) 2349-2354
8. Anderson T.J., Elstein E., Haber H., and Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 35 (2000) 60-66
9. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 (1995) 1235-1241
10. Warnholtz A., Ostad M.A., Heitzer T., et al. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease. Am J Cardiol 95 (2005) 20-23
11. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin on Recovery of coronary Endothelial function). Circulation 2003;107:422-8.
12. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47 (2001) 418-425
13. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 10 (2005) 1-7
14. Schwedhelm E., Tsikas D., Durand T., et al. Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine. J Chromatogr B Biomed Sci Appl 744 (2000) 99-112
15. Preumont N., Unger P., Goldman S., and Berkenboom G. Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion. Cardiovasc Drugs Ther 18 (2004) 197-202
16. Lerman A., Holmes Jr. D.R., Bell M.R., et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92 (1995) 2426-2431
17. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
18. Schwedhelm E., Bartling A., Lenzen H., et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 109 (2004) 843-848
19. Sydow K., and Munzel T. ADMA and oxidative stress. Atheroscler Suppl 4 (2003) 41-51
20. Prasad A., Koh K.K., Schenke W.H., et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 142 (2001) 248-253
21. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 42 (2003) 905-910
22. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
23. Gokce N., Keaney Jr. J.F., Hunter L.M., et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105 (2002) 1567-1572